Bristol-Myers Squibb Company— Quarterly & Annual Financial Results
Historical Earnings Data
View Bristol-Myers Squibb Company's (BMY) complete earnings history including revenue, EPS, net income, and profit margins. Data sourced from SEC EDGAR filings and updated after every earnings report.
12.5B
Q4 2025
$0.53
Diluted
1.3%
Growth
8
Quarterly reports
Bristol-Myers Squibb Company most recently reported on March 31, 2026, posting diluted EPS of $1.58 against an analyst estimate of $1.43 — a beat of 10.4%.
Over the last 4 reported quarters, BMY has beaten EPS estimates in 4 (100% hit rate). Most recent quarterly revenue grew 1.3% year-over-year. Gross margin expanded 7.1 percentage points compared to the same quarter a year prior.
| Date | EPS Est. | EPS Actual | Surprise | Rev. Est. | Rev. Actual | Result |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | $1.43 | $1.58 | +10.4% | — | — | Beat |
| Dec 31, 2025 | $1.13 | $1.26 | +11.9% | — | — | Beat |
| Sep 30, 2025 | $1.52 | $1.63 | +6.9% | — | — | Beat |
| Jun 30, 2025 | $1.08 | $1.46 | +35.0% | — | — | Beat |
| Quarter | Revenue | Net Income | EPS | Gross Margin | Net Margin |
|---|---|---|---|---|---|
| Q4 2025 | 12.5B | 1.1B | $0.53 | 67.2% | 8.7% |
| Q3 2025 | 12.2B | 2.2B | $1.08 | 71.9% | 18.0% |
| Q2 2025 | 12.3B | 1.3B | $0.64 | 65.8% | 10.7% |
| Q1 2025 | 11.2B | 2.5B | $1.20 | 65.5% | 21.9% |
| Q4 2024 | 12.3B | 72.0M | $0.04 | 60.2% | 0.6% |
| Q3 2024 | 11.9B | 1.2B | $0.60 | 55.6% | 10.2% |
| Q2 2024 | 12.2B | 1.7B | $0.83 | 55.7% | 13.8% |
| Q1 2024 | 11.9B | -11,911,000,000 | $-5.89 | 55.5% | -100.4% |
AI insights, news & charts
Form 4 buys & sells
Translate filings to English
Bristol-Myers Squibb Company (BMY) reports quarterly earnings in accordance with SEC regulations. Each earnings report includes the income statement (revenue, cost of goods sold, gross profit, operating income, and net income), the balance sheet, and the cash flow statement. The data shown above is sourced directly from Bristol-Myers Squibb Company's SEC filings on the EDGAR database.
Earnings Per Share (EPS) is the most closely watched metric during earnings season. Diluted EPS accounts for all potential shares from stock options and convertible securities, making it the more conservative and meaningful measure. When BMYreports EPS above the consensus analyst estimate, it's called an "earnings beat," which typically causes the stock to rise.
Profit margins reveal operational efficiency. Gross margin shows how much revenue remains after subtracting the cost of goods sold, while net margin shows the final profit after all expenses, taxes, and interest. Expanding margins often signal improving business fundamentals, while contracting margins can be a warning sign.
Disclaimer: Financial data for Bristol-Myers Squibb Company (BMY) is sourced from SEC filings and may contain processing errors. This data is provided for informational purposes only and does not constitute investment advice. Always verify data from official sources and consult a financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings call summaries and financial analysis for Bristol-Myers Squibb Company within hours of every report.
Join the Waitlist